nach oben

Current Diabetes Reports

Erschienen in:

01.09.2019 | Debate

Debate on Insulin vs Non-insulin Use in the Hospital Setting—Is It Time to Revise the Guidelines for the Management of Inpatient Diabetes?

verfasst von: Francisco J. Pasquel, Maya Fayfman, Guillermo E. Umpierrez

Erschienen in: Current Diabetes Reports | Ausgabe 9/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Hyperglycemia contributes to a significant increase in morbidity, mortality, and healthcare costs in the hospital. Professional associations recommend insulin as the mainstay of diabetes therapy in the inpatient setting. The standard of care basal–bolus insulin regimen is a labor-intensive approach associated with a significant risk of iatrogenic hypoglycemia. This review summarizes recent evidence from observational studies and clinical trials suggesting that not all patients require treatment with complex insulin regimens.

Recent Findings

Evidence from clinical trials shows that incretin-based agents are effective in appropriately selected hospitalized patients and may be a safe alternative to complicated insulin regimens. Observational studies also show that older agents (i.e., metformin and sulfonylureas) are commonly used in the hospital, but there are few carefully designed studies addressing their efficacy.

Summary

Therapy with dipeptidyl peptidase-4 (DPP-4) inhibitors, alone or in combination with basal insulin, may effectively control glucose levels in patients with mild to moderate hyperglycemia. Further studies with glucagon-like peptide-1 (GLP-1) receptor analogs and older oral agents are needed to confirm their safety in the hospital.

Umpierrez GE, Hellman R, Korytkowski MT, Kosiborod M, Maynard GA, Montori VM, et al. Management of hyperglycemia in hospitalized patients in non-critical care setting: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2012;97(1):16–38.CrossRef

Moghissi ES, Korytkowski MT, DiNardo M, Einhorn D, Hellman R, Hirsch IB, et al. American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Diabetes Care. 2009;32(6):1119–31.PubMedPubMedCentralCrossRef

Umpierrez GE, Isaacs SD, Bazargan N, You X, Thaler LM, Kitabchi AE. Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes. J Clin Endocrinol Metab. 2002;87(3):978–82.CrossRef

Frisch A, Chandra P, Smiley D, Peng L, Rizzo M, Gatcliffe C, et al. Prevalence and clinical outcome of hyperglycemia in the perioperative period in noncardiac surgery. Diabetes Care. 2010;33(8):1783–8.PubMedPubMedCentralCrossRef

Pasquel FJ, Smiley D, Spiegelman R, Lin E, Peng L, Umpierrez GE. Hyperglycemia is associated with increased hospital complications and mortality during parenteral nutrition. Hosp Pract (Minneap). 2011;39(2):81–8.PubMedCrossRef

Finney SJ, Zekveld C, Elia A, Evans TW. Glucose control and mortality in critically ill patients. Jama. 2003;290(15):2041–7.PubMedCrossRef

Kotagal M, Symons RG, Hirsch IB, Umpierrez GE, Dellinger EP, Farrokhi ET, et al. Perioperative hyperglycemia and risk of adverse events among patients with and without diabetes. Ann Surg. 2015;261(1):97–103.PubMedPubMedCentralCrossRef

Hua J, Chen G, Li H, Fu SK, Zhang LM, Scott M, et al. Intensive intraoperative insulin therapy versus conventional insulin therapy during cardiac surgery: a meta-analysis. J Cardiothorac Vasc Anesth. 2012;26(5):829–34.PubMedCrossRef

Krinsley JS, Maurer P, Holewinski S, et al. Glucose control, diabetes status, and mortality in critically ill patients: The Continuum From Intensive Care Unit Admission to Hospital Discharge. Mayo Clin Proc. 2017;92(7):1019–29.PubMedCrossRef

10.

Kwon S, Thompson R, Dellinger P, Yanez D, Farrohki E, Flum D. Importance of perioperative glycemic control in general surgery: a report from the Surgical Care and Outcomes Assessment Program. Ann Surg. 2013;257(1):8–14.PubMedPubMedCentralCrossRef

11.

Umpierrez GE, Smiley D, Jacobs S, Peng L, Temponi A, Mulligan P, et al. Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes undergoing general surgery (RABBIT 2 surgery). Diabetes Care. Feb 2011;34(2):256–61.PubMedPubMedCentralCrossRef

12.

Umpierrez G, Cardona S, Pasquel F, Jacobs S, Peng L, Unigwe M, et al. Randomized controlled trial of intensive versus conservative glucose control in patients undergoing coronary artery bypass graft surgery: GLUCO-CABG trial. Diabetes Care. Sep 2015;38(9):1665–72.PubMedPubMedCentralCrossRef

13.

van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, et al. Intensive insulin therapy in the critically ill patients. N Engl J Med. 2001;345(19):1359–67.PubMedCrossRef

14.

Okabayashi T, Shima Y, Sumiyoshi T, Kozuki A, Tokumaru T, Iiyama T, et al. Intensive versus intermediate glucose control in surgical intensive care unit patients. Diabetes Care. 2014;37(6):1516–24.PubMedCrossRef

15.

Kyi M, Colman PG, Wraight PR, et al. Early Intervention for Diabetes in Medical and Surgical Inpatients Decreases Hyperglycemia and Hospital-Acquired Infections: A Cluster Randomized Trial. Diabetes Care. 2019;42(5):832–40.

16.

Clement S, Braithwaite SS, Magee MF, Ahmann A, Smith EP, Schafer RG, et al. Management of diabetes and hyperglycemia in hospitals. Diabetes Care. 2004;27(2):553–97.PubMedCrossRef

17.

Umpierrez GE, Hor T, Smiley D, Temponi A, Umpierrez D, Ceron M, et al. Comparison of inpatient insulin regimens with detemir plus aspart versus neutral protamine hagedorn plus regular in medical patients with type 2 diabetes. J Clin Endocrinol Metab. 2009;94(2):564–9.CrossRef

18.

Umpierrez GE, Smiley D, Zisman A, Prieto LM, Palacio A, Ceron M, et al. Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes (RABBIT 2 trial). Diabetes Care. 2007;30(9):2181–6.PubMedCrossRef

19.

American Diabetes A. 14. Diabetes care in the hospital: standards of medical care in diabetes-2018. Diabetes Care. 2018;41(Suppl 1):S144–51.

20.

Umpierrez GE, Smiley D, Hermayer K, Khan A, Olson DE, Newton C, et al. Randomized study comparing a basal-bolus with a basal plus correction insulin regimen for the hospital management of medical and surgical patients with type 2 diabetes: basal plus trial. Diabetes Care. 2013;36(8):2169–74.PubMedPubMedCentralCrossRef

21.

Turchin A, Matheny ME, Shubina M, Scanlon JV, Greenwood B, Pendergrass ML. Hypoglycemia and clinical outcomes in patients with diabetes hospitalized in the general ward. Diabetes Care. 2009;32(7):1153–7.PubMedPubMedCentralCrossRef

22.

Nirantharakumar K, Marshall T, Kennedy A, Narendran P, Hemming K, Coleman JJ. Hypoglycaemia is associated with increased length of stay and mortality in people with diabetes who are hospitalized. Diabet Med. 2012;29(12):e445–8.PubMedCrossRef

23.

Umpierrez GE, Korytkowski M. Is incretin-based therapy ready for the care of hospitalized patients with type 2 diabetes?: insulin therapy has proven itself and is considered the mainstay of treatment. Diabetes Care. 2013;36(7):2112–7.PubMedPubMedCentralCrossRef

24.

Umpierrez GE, Schwartz S. Use of incretin-based therapy in hospitalized patients with hyperglycemia. 2014;20(9):933–44.

25.

Umpierrez GE, Gianchandani R, Smiley D, Jacobs S, Wesorick DH, Newton C, et al. Safety and efficacy of sitagliptin therapy for the inpatient management of general medicine and surgery patients with type 2 diabetes: a pilot, randomized, controlled study. Diabetes Care. 2013;36(11):3430–5.PubMedPubMedCentralCrossRef

26.

Vellanki P, Rasouli N, Baldwin D, et al. Glycaemic Efficacy and Safety of Linagliptin compared to Basal-Bolus Insulin Regimen in Patients with Type 2 Diabetes Undergoing Non-Cardiac Surgery: A Multicenter Randomized Clinical Trial. Diabetes Obes Metab. 2018 Nov 20. https://doi.org/10.1111/dom.13587.CrossRef

27.

Garg R, Schuman B, Hurwitz S, Metzger C, Bhandari S. Safety and efficacy of saxagliptin for glycemic control in non-critically ill hospitalized patients. BMJ Open Diabetes Res Care. 2017;5(1):e000394.PubMedPubMedCentralCrossRef

28.

Perez-Belmonte LM, Gomez-Doblas JJ, Millan-Gomez M, et al. Use of Linagliptin for the Management of Medicine Department Inpatients with Type 2 Diabetes in Real-World Clinical Practice (Lina-Real-World Study). J Clin Med. 2018;7(9):271.PubMedCentralCrossRef

29•.

Fayfman M, Galindo RJ, Rubin DJ, et al. A Randomized Controlled Trial on the Safety and Efficacy of Exenatide Therapy for the Inpatient Management of General Medicine and Surgery Patients With Type 2 Diabetes. Diabetes Care. 2019;42(3):450–56. This pilot clinical trial suggested that exenatide alone or in combination with basal insulin is safe and effective for the management of hospitalized general medical and surgical patients with T2D. PubMedCrossRef

30•.

Pasquel FJ, Gianchandani R, Rubin DJ, et al. Efficacy of sitagliptin for the hospital management of general medicine and surgery patients with type 2 diabetes (Sita-Hospital): a multicentre, prospective, open-label, non-inferiority randomised trial. Lancet Diabetes Endocrinol. 2017;5(2):125–33. This study showed most patients with mild to moderate hyperglycemia can effectively be treated with basal insulin along with a DPP-4 inhibitor in the hospital. PubMedCrossRef

31.

Montejano L, Vo L, McMorrow D. Transitions of care for people with type 2 diabetes: utilization of antihyperglycemic agents pre- and post-hospitalization. Diagn Ther. 2016;7(1):91–103.

32.

Bishay RH, Meyerowitz-Katz G, Chandrakumar D, Jayaballa R, Hng TM, Mclean M, et al. Evaluating the diabetes-cardiology interface: a glimpse into the diabetes management of cardiology inpatients in western Sydney’s ‘diabetes hotspot’ and the establishment of a novel model of care. Diabetol Metab Syndr. 2018;10:90.

33.

Satpathy SV, Datta S, Upreti B. Utilization study of antidiabetic agents in a teaching hospital of Sikkim and adherence to current standard treatment guidelines. J Pharm Bioallied Sci. 2016;8(3):223–8.PubMedPubMedCentralCrossRef

34.

Rajendran R, Kerry C, Rayman G, GICsg M. Temporal patterns of hypoglycaemia and burden of sulfonylurea-related hypoglycaemia in UK hospitals: a retrospective multicentre audit of hospitalised patients with diabetes. BMJ Open. 2014;4(7):e005165.PubMedPubMedCentralCrossRef

35.

Sultana G, Kapur P, Aqil M, Alam MS, Pillai KK. Drug utilization of oral hypoglycemic agents in a university teaching hospital in India. J Clin Pharm Ther. 2010;35(3):267–77.PubMedCrossRef

36.

Scotton DW, Wierman H, Coughlan A, Walters M, Kuhn C. Assessing the appropriate use of metformin in an inpatient setting and the effectiveness of two pharmacy-based measures to improve guideline adherence. Qual Manag Health Care. 2009;18(1):71–6.PubMedCrossRef

37.

Sharabash HM, Remington TL, Mar P, Winston R, Walker PC. Retrospective review of metformin in inpatients and outpatients at the University of Michigan. Diabetes Care. Jan 2006;29(1):170–1.PubMed

38.

Haltmeier T, Benjamin E, Beale E, Inaba K, Demetriades D. Insulin-treated patients with diabetes mellitus undergoing emergency abdominal surgery have worse outcomes than patients treated with oral agents. World J Surg. 2016;40(7):1575–82.PubMedCrossRef

39.

Waki N, Memon A, Khan MO, et al. Current understanding of treatment and management protocol for adult diabetic in-patients at a tertiary care hospital. J Pak Med Assoc. 2012;62(5):520–4.PubMed

40.

Vengurlekar S, Shukla P, Patidar P, Bafna R, Jain S. Prescribing pattern of antidiabetic drugs in Indore city hospital. Indian J Pharm Sci. 2008;70(5):637–40.PubMedPubMedCentralCrossRef

41.

Kodner C, Anderson L, Pohlgeers K. Glucose management in hospitalized patients. Am Fam Physician. 2017;96(10):648–54.PubMed

42.

Gianchandani RY, Pasquel FJ, Rubin DJ, Dungan KM, Vellanki P, Wang H, et al. The efficacy and safety of co-administration of sitagliptin with metformin in patients with type 2 diabetes at hospital discharge. Endocr Pract. 2018;24(6):556–64.PubMedPubMedCentralCrossRef

43.

Karamanos E, Sivrikoz E, Beale E, Chan L, Inaba K, Demetriades D. Effect of diabetes on outcomes in patients undergoing emergent cholecystectomy for acute cholecystitis. World J Surg. 2013;37(10):2257–64.PubMedCrossRef

44.

Pasquel FJ, Klein R, Adigweme A, et al. Metformin-associated lactic acidosis. Am J Med Sci. 2015;349(3):263–7.PubMedCrossRef

45.

Madiraju AK, Erion DM, Rahimi Y, Zhang XM, Braddock DT, Albright RA, et al. Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature. 2014;510(7506):542–6.PubMedPubMedCentralCrossRef

46.

Madiraju AK, Qiu Y, Perry RJ, Rahimi Y, Zhang XM, Zhang D, et al. Metformin inhibits gluconeogenesis via a redox-dependent mechanism in vivo. Nat Med. Sep 2018;24(9):1384–94.PubMedPubMedCentralCrossRef

47.

Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev. 2010;14(4):CD002967.

48.

FDA revises warnings regarding use of the diabetes medicine metformin in certain patients with reduced kidney function. https://www.fda.gov/downloads/Drugs/DrugSafety/UCM494140.pdf Accessed April 6, 2019.

49.

Mima Y, Kuwashiro T, Yasaka M, Tsurusaki Y, Nakamura A, Wakugawa Y, et al. Impact of metformin on the severity and outcomes of acute ischemic stroke in patients with type 2 diabetes mellitus. J Stroke Cerebrovasc Dis. 2016;25(2):436–46.PubMedCrossRef

50.

Sarfo-Adu BN, Hendley JL, Pick B, Oyibo SO. Glycemic control during enteral tube feeding in patients with diabetes mellitus. Cureus. 2019;11(1):e3929.PubMedPubMedCentral

51.

Lepelley M, Giai J, Yahiaoui N, Chanoine S, Villier C. Lactic acidosis in diabetic population: is metformin implicated? Results of a matched case-control study performed on the type 2 diabetes population of Grenoble Hospital University. J Diabetes Res. 2016;2016:3545914.PubMedPubMedCentralCrossRef

52.

Tsivgoulis G, Goyal N, Iftikhar S, Zand R, Chang JJ, Elijovich L, et al. Sulfonylurea pretreatment and in-hospital use does not impact acute ischemic strokes (AIS) outcomes following intravenous thrombolysis. J Stroke Cerebrovasc Dis. 2017;26(4):795–800.PubMedCrossRef

53.

Kunte H, Schmidt S, Eliasziw M, del Zoppo GJ, Simard JM, Masuhr F, et al. Sulfonylureas improve outcome in patients with type 2 diabetes and acute ischemic stroke. Stroke. 2007;38(9):2526–30.PubMedPubMedCentralCrossRef

54.

Irvine H, Male S, Robertson J, Bell C, Bentho O, Streib C. Reduced intracerebral hemorrhage and perihematomal edema volumes in diabetics on sulfonylureas. Stroke. 2019;50(4):995–8.PubMedCrossRef

55.

Caffes N, Kurland DB, Gerzanich V, Simard JM. Glibenclamide for the treatment of ischemic and hemorrhagic stroke. Int J Mol Sci. 2015;16(3):4973–84.PubMedPubMedCentralCrossRef

56.

Kurland DB, Tosun C, Pampori A, et al. Glibenclamide for the treatment of acute CNS injury. Pharmaceuticals (Basel). 2013;6(10):1287–303.PubMedPubMedCentralCrossRef

57.

Mehta RI, Tosun C, Ivanova S, Tsymbalyuk N, Famakin BM, Kwon MS, et al. Sur1-Trpm4 cation channel expression in human cerebral infarcts. J Neuropathol Exp Neurol. 2015;74(8):835–49.CrossRef

58.

Deusenberry CM, Coley KC, Korytkowski MT, Donihi AC. Hypoglycemia in hospitalized patients treated with sulfonylureas. Pharmacotherapy. 2012;32(7):613–7.PubMedCrossRef

59.

Stuart K, Adderley NJ, Marshall T, Rayman G, Sitch A, Manley S, et al. Predicting inpatient hypoglycaemia in hospitalized patients with diabetes: a retrospective analysis of 9584 admissions with diabetes. Diabetic Med. 2017;34(10):1385–91.PubMedCrossRef

60.

Heaton PC, Desai VC, Kelton CM, Rajpathak SN. Sulfonylurea use and the risk of hospital readmission in patients with type 2 diabetes. BMC Endocr Disord. 2016;16:4.PubMedPubMedCentralCrossRef

61.

Khalam A, Dilip C, Shinu C. Drug use evaluation of diabetes mellitus in hospitalized patients of a tertiary care referral hospital. J Basic Clin Physiol Pharmacol. 2012;23(4):173–7.PubMedCrossRef

62.

Bolen S, Feldman L, Vassy J, Wilson L, Yeh HC, Marinopoulos S, et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med. 2007;147(6):386–99.PubMedCrossRef

63.

Lee J, Reding M. Effects of thiazolidinediones on stroke recovery: a case-matched controlled study. Neurochem Res. 2007;32(4–5):635–8.PubMedCrossRef

64.

Kernan WN, Viscoli CM, Furie KL, Young LH, Inzucchi SE, Gorman M, et al. Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med. 7 2016;374(14):1321–31.

65.

Schwartz SS, DeFronzo RA, Umpierrez GE. Practical implementation of incretin-based therapy in hospitalized patients with type 2 diabetes. Postgrad Med. 2015;127(2):251–7.PubMedCrossRef

66.

Jespersen MJ, Knop FK, Christensen M. GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations. Expert Opin Drug Metab Toxicol. 2013;9(1):17–29.CrossRef

67.

Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–44.PubMedCrossRef

68.

Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–22.PubMedCrossRef

69.

Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121–130.

70.

Hernandez AF, Green JB, Janmohamed S, D'Agostino RB Sr, Granger CB, Jones NP, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018;392(10157):1519–29.

71.

Abuannadi M, Kosiborod M, Riggs L, House J, Hamburg M, Kennedy K, et al. Management of hyperglycemia with the administration of intravenous exenatide to patients in the cardiac intensive care unit. Endocr Pract. 2013;19(1):81–90.PubMedCrossRef

72.

Kohl BA, Hammond MS, Cucchiara AJ, Ochroch EA. Intravenous GLP-1 (7-36) amide for prevention of hyperglycemia during cardiac surgery: a randomized, double-blind, placebo-controlled study. J Cardiothorac Vasc Anesth. 2014;28(3):618–25.PubMedCrossRef

73.

Besch G, Perrotti A, Mauny F, Puyraveau M, Baltres M, Flicoteaux G, et al. Clinical effectiveness of intravenous exenatide infusion in perioperative glycemic control after coronary artery bypass graft surgery: a phase II/III randomized trial. Anesthesiology. 2017;127(5):775–87.PubMedCrossRef

74•.

Polderman JAW, van Steen SCJ, Thiel B, Godfried MB, Houweling PL, Hollmann MW, et al. Peri-operative management of patients with type-2 diabetes mellitus undergoing non-cardiac surgery using liraglutide, glucose-insulin-potassium infusion or intravenous insulin bolus regimens: a randomised controlled trial. Anaesthesia. 2018;73(3):332–9. Findings from this study suggest GLP-1RA can improve glycemic control in the perioperative period.PubMedCrossRef

75.

Pasquel FJ, Gomez-Huelgas R, Anzola I, Oyedokun F, Haw JS, Vellanki P, et al. Predictive value of admission hemoglobin A1c on inpatient glycemic control and response to insulin therapy in medicine and surgery patients with type 2 diabetes. Diabetes Care. 2015;38(12):e202–3.PubMedPubMedCentralCrossRef

76.

Nystrom T, Gutniak MK, Zhang Q, et al. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab. 2004;287(6):E1209–15.PubMedCrossRef

77.

Lonborg J, Kelbaek H, Vejlstrup N, et al. Exenatide reduces final infarct size in patients with ST-segment-elevation myocardial infarction and short-duration of ischemia. Circ Cardiovasc Interv. 2012;5(2):288–95.

78.

Sokos GG, Nikolaidis LA, Mankad S, Elahi D, Shannon RP. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail. 2006;12(9):694–9.PubMedCrossRef

79.

Nathanson D, Ullman B, Lofstrom U, et al. Effects of intravenous exenatide in type 2 diabetic patients with congestive heart failure: a double-blind, randomised controlled clinical trial of efficacy and safety. Diabetologia. 2012;55(4):926–35.PubMedCrossRef

80.

Sokos GG, Bolukoglu H, German J, Hentosz T, Magovern GJ Jr, Maher TD, et al. Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting. Am J Cardiol. 2007;100(5):824–9.PubMedCrossRef

81.

Nikolaidis LA, Mankad S, Sokos GG, Miske G, Shah A, Elahi D, et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation. 2004;109(8):962–5.PubMedCrossRef

82.

Besch G, Perrotti A, Salomon du Mont L, Puyraveau M, Ben-Said X, Baltres M, et al. Impact of intravenous exenatide infusion for perioperative blood glucose control on myocardial ischemia-reperfusion injuries after coronary artery bypass graft surgery: sub study of the phase II/III ExSTRESS randomized trial. Cardiovasc Diabetol. 2018;17(1):140.

83.

Mecott GA, Herndon DN, Kulp GA, Brooks NC, al-Mousawi AM, Kraft R, et al. The use of exenatide in severely burned pediatric patients. Crit Care. 2010;14(4):R153.PubMedPubMedCentralCrossRef

84.

Hulst AH, Visscher MJ, Godfried MB, Thiel B, Gerritse BM, Scohy TV, et al. Study protocol of the randomised placebo-controlled GLOBE trial: GLP-1 for bridging of hyperglycaemia during cardiac surgery. BMJ Open. 2018;8(6):e022189.PubMedPubMedCentralCrossRef

85.

Hsia DS, Grove O, Cefalu WT. An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus. Curr Opin Endocrinol Diabetes Obes. 2017;24(1):73–9.PubMedPubMedCentral

86.

Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–28.PubMedCrossRef

87.

Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–57.PubMedCrossRef

88.

Erondu N, Desai M, Ways K, Meininger G. Diabetic ketoacidosis and related events in the canagliflozin type 2 diabetes clinical program. Diabetes Care. 2015;38(9):1680–6.PubMedPubMedCentralCrossRef

Titel: Debate on Insulin vs Non-insulin Use in the Hospital Setting—Is It Time to Revise the Guidelines for the Management of Inpatient Diabetes?
verfasst von: Francisco J. Pasquel
Maya Fayfman
Guillermo E. Umpierrez
Publikationsdatum: 01.09.2019
Verlag: Springer US
Erschienen in: Current Diabetes Reports / Ausgabe 9/2019
Print ISSN: 1534-4827
Elektronische ISSN: 1539-0829
DOI: https://doi.org/10.1007/s11892-019-1184-8

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2019

Alterations in Beta Cell Identity in Type 1 and Type 2 Diabetes

Can the Routine Use of Patient-Reported Outcome Measures Improve the Delivery of Person-Centered Diabetes Care? A Review of Recent Developments and a Case Study

Nutritional Supplementation for the Prevention and/or Treatment of Gestational Diabetes Mellitus

The Beta Cell in Type 2 Diabetes

Scaling Up Teleophthalmology for Diabetic Eye Screening: Opportunities for Widespread Implementation in the USA

Klinefelter Syndrome and Diabetes